Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges

Abdullahi, Idris Nasir; Emeribe, Anthony Uchenna; Adekola, Hafeez Aderinsayo; Abubakar, Sharafudeen Dahiru; Dangana, Amos; Shuwa, Halima Ali; Nwoba, Sunday Theophilus; Mustapha, Jelili Olaide; Haruna, Muyideen; Olowookere, Kafayat Adepeju; Animasaun, Olawale Sunday; Ugwu, Charles Egede; Onoja, Solomon Oloche; Gadama, Abdullahi Sani; Mohammed, Musa; Daneji, Isa Muhammad; Amadu, Dele Ohinoyi; Ghamba, Peter Elisha; Onukegbe, Nkechi Blessing; Shehu, Muhammad Sagir; Chiladi, Isomah; Babayo, Adamu; Ahmad, Abdurrahman Elfulaty

doi:10.1080/21645515.2020.1812313

Cited by 3 publications

(3 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Worrying about the epidemic and closely monitoring media coverage were consistent forecasting parameters of health protection behaviours and vaccination intentions. With growing demand, the availability of a COVID‐19 vaccine is touted as the solution to controlling the current COVID‐19 pandemic, reducing the number of infections and deaths, and facilitating the resumption of our previous lifestyle (Abdullahi et al, 2021; Begum et al, 2021).…”

Section: State Of the Art And Problem Statementmentioning

confidence: 99%

A hybrid approach based on ELECTRE III‐genetic algorithm and TOPSIS method for selection of optimal COVID‐19 vaccines

Forestal

2021

Multi Criteria Decision Anal

View full text Add to dashboard Cite

COVID‐19 pandemic poses unprecedented challenges to the world health system, prompting academics and health professionals to develop appropriate solutions. Researchers reported different COVID‐19 vaccines introduced by institutions and companies around the globe, which are at different stages of development. However, research developing an integrated framework for selecting and ranking the optimal potential vaccine against COVID‐19 is minimal. This paper aimed to fill this gap by using a hybrid methodology based on ELimination Et Choice Translating REality III (ELECTRE III)–Genetic Algorithm (GA) and Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) approach to select the optimal SARS‐CoV‐2 vaccine. ELECTRE III method yields a fathomable analysis of the concordance index, while GA is known for its ability to disaggregate decision‐making preferences from holistic decisions. TOPSIS is preferred for picking an ideal and an anti‐ideal solution. Thus, combining ELECTRE III‐GA and TOPSIS is considered the best model to assess vaccines against the pandemic. The results confirm that the best vaccines rely on a high level of safety, efficacy, and availability. Our developed evaluation framework can help healthcare professionals and researchers gain research information and make critical decisions regarding potential vaccines against the disease.

show abstract

Section: State Of the Art And Problem Statementmentioning

confidence: 99%

A hybrid approach based on ELECTRE III‐genetic algorithm and TOPSIS method for selection of optimal COVID‐19 vaccines

Forestal

2021

Multi Criteria Decision Anal

View full text Add to dashboard Cite

show abstract

“…Recent research shows that SARS-CoV-2 infection triggers the induction of both innate and adaptive immune responses by the infected person, which play essential roles in the elimination of the viral infection [20][21][22][23][24][25][26][27][28]. However, the over-activated innate immune responses and impaired adaptive immune responses may result in immunopathology leading to severe local and systemic tissue damage in the patient [29][30][31][32][33]. The process of SARS-CoV-2 entry into the cells involves the participation of several key proteins from both the virus and the host cells.…”

Section: Some Recent Findings On the Immunobiology Of Sars-cov-2 Infe...mentioning

confidence: 99%

Antibody-Based Immunotherapeutic Strategies for COVID-19

et al. 2020

View full text Add to dashboard Cite

Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.

show abstract

“…Although substantial improvement in clinical research has led to a better understanding of the novel SAR-CoV-2 infection and the management of COVID-19 disease, limiting the virus's continuing spread has become an issue due to the virus's rapid mutation. It has been proven beyond doubt that timely vaccines can prevent several life-threatening diseases, and the average lifespan in most countries has substantially improved owing to these developments [5,6]. Hence, successful vaccines are in urgent need to battle against COVID-19 disease.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Adenoviral Vector-Based Vaccines for Prevention of Covid-19 – An Overview

SHANMUGAM

Sriram²,

George³

2022

Asian J Pharm Clin Res

View full text Add to dashboard Cite

The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19.

show abstract

Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges

Cited by 3 publications

References 131 publications

A hybrid approach based on ELECTRE III‐genetic algorithm and TOPSIS method for selection of optimal COVID‐19 vaccines

A hybrid approach based on ELECTRE III‐genetic algorithm and TOPSIS method for selection of optimal COVID‐19 vaccines

Antibody-Based Immunotherapeutic Strategies for COVID-19

Evaluation of Adenoviral Vector-Based Vaccines for Prevention of Covid-19 – An Overview

Contact Info

Product

Resources

About